Ascendis Pharma (ASND) officer reports warrants, RSUs and shares
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Ascendis Pharma A/S officer Jensen Flemming Steen filed an initial ownership report showing a mix of ordinary shares, warrants, and restricted stock units tied to the company’s equity. He holds 19,460 ordinary shares directly, including American Depositary Shares where each ADS represents one ordinary share.
His derivative position includes fully vested, currently exercisable warrants over 20,000, 27,000, 22,755 and 14,504 ordinary shares at exercise prices of 62.1700, 108.0000, 176.2800 and 139.6500 respectively. He also holds restricted stock units covering 4,246, 3,197 and 9,552 ordinary shares, each RSU representing a contingent right to receive one ADS. These RSUs vest over time beginning on March 1, 2027 and have no expiration date.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
JENSEN FLEMMING STEEN
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Warrants — 20,000 shares (Direct);
Restricted Stock Units — 4,246 shares (Direct);
Ordinary Shares — 19,460 shares (Direct)
Footnotes (1)
- Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share. The warrants are fully vested and currently exercisable. The restricted stock units vest on March 1, 2027 and have no expiration date. Each restricted stock unit represents a contingent right to receive one ADS. The restricted stock units vest in two equal annual installments beginning on March 1, 2027. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.
FAQ
What did Ascendis Pharma (ASND) disclose in Jensen Flemming Steen’s Form 3?
Ascendis Pharma reported officer Jensen Flemming Steen’s existing equity holdings. The filing details his direct ownership of ordinary shares, fully vested warrants, and multiple restricted stock unit grants that vest beginning March 1, 2027, outlining his overall long-term equity exposure to the company.
What warrant positions are reported for Jensen Flemming Steen in Ascendis Pharma (ASND)?
He holds fully vested, currently exercisable warrants over 20,000, 27,000, 22,755 and 14,504 ordinary shares. Exercise prices are 62.1700, 108.0000, 176.2800 and 139.6500, with expiration dates between December 2028 and December 2031.
What restricted stock units does Jensen Flemming Steen hold in Ascendis Pharma?
He holds RSUs covering 4,246, 3,197 and 9,552 ordinary shares. Each restricted stock unit represents a contingent right to receive one ADS and vests in scheduled annual installments beginning on March 1, 2027, with no expiration date specified for these awards.
Do the warrants and RSUs in this Ascendis Pharma Form 3 involve new transactions?
The Form 3 lists holdings but shows no buy or sell transactions. All entries are classified as holdings, with transaction codes unspecified, indicating this filing serves as an initial snapshot of existing positions rather than reporting new market activity.
How do the Ascendis Pharma RSUs for Jensen Flemming Steen vest over time?
Some RSUs vest fully on March 1, 2027, while others vest in two or three equal annual installments starting that date. This creates a multi-year vesting schedule that gradually delivers ADSs, aligning a portion of his compensation with future company performance.